Xoma Corp Depositary Shares (NQ: XOMAO )

25.58 -0.02 (-0.07%)

Streaming Delayed Price Updated: 3:15 PM EDT, Nov 1, 2024 Add to My Watchlist

Price and Volume

Volume	1,620
Open	25.56
Bid (Size)	25.55 (15)
Ask (Size)	25.64 (2)
Prev. Close	25.60
Today's Range	25.56 - 25.62
52wk Range	21.51 - 25.87
Shares Outstanding	N/A
Dividend Yield	8.18%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

October 22, 2024

From XOMA Corporation

Via GlobeNewswire

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

September 23, 2024

From XOMA Corporation

Via GlobeNewswire

Performance

YTD	+2.74%	+2.74%
1 Month	-0.69%	-0.69%
3 Month	+0.32%	+0.32%
6 Month	+2.35%	+2.35%
1 Year	+16.28%	+16.28%

More News

XOMA Royalty Declares Quarterly Preferred Stock Dividends

September 23, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Royalty to Present at Upcoming Investor Conferences in September

September 04, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

August 13, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Declares Quarterly Preferred Stock Dividends

June 20, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

June 12, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

May 14, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

May 09, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

April 30, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

April 25, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Corporation Announces Closing of Tender Offer

April 03, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Declares Quarterly Preferred Stock Dividends

March 21, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

March 19, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

March 08, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA to Present at Upcoming Investor Conferences in March

February 28, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

February 16, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

January 18, 2024

From XOMA Corporation

Via GlobeNewswire

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

January 11, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

January 08, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Announces Stock Repurchase Program of up to $50 Million

January 02, 2024

From XOMA Corporation

Via GlobeNewswire

XOMA Declares Quarterly Preferred Stock Dividends

December 20, 2023

From XOMA Corporation

Via GlobeNewswire

XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties

December 19, 2023

From XOMA Corporation

Via GlobeNewswire

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

November 07, 2023

From XOMA Corporation

Via GlobeNewswire

XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

October 31, 2023

From XOMA Corporation

Via GlobeNewswire

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.